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Chronic lymphocytic leukemia (CLL) is the most common
leukemia, accounting for 25% to 30% of all leukemia in the
Western world. Generally, CLL is considered incurabled
although readily controllabledwith combination therapies,
including purine analogues, monoclonal antibodies, and
newer targeted agents, such as ibrutinib [1]. Furthermore,
heterogeneous outcomes result from different prognostic
features at diagnosis or during evolution of disease. However,
long-term disease-free survival (DFS) is increasingly possible
with hematopoietic cell transplantation (HCT). This review
will synthesize the data demonstrating lack of overall sur-
vival beneﬁt for autologous HCT, provide outcomes for allo-
geneic HCT, and discuss novel cellular approaches in
development to further decrease relapse risk.AUTOLOGOUS HCT
Autologous HCT was initially reported in management of
CLL in 1993, and a retrospective analysis published in 2004
documented improved overall survival (OS) for patients with
unmutated immunoglobulin variable region heavy chain
(IGVH) [2]. Since that time, several analyses, including ran-
domized controlled trials, have demonstrated an improved
event-free survival (EFS) with autologous HCT as consolida-
tion for ﬁrst or second remission; however, no beneﬁt in OS
is noted [3-6]. The three randomized trials all used what is
now considered to be suboptimal initial therapy, before the
development of combination chemotherapy with ﬂudar-
abine, cyclophosphamide (CY), and rituximab (FCR) as the
standard of care [7].
In 2011, the Société Française de Greffe de Moelle et de
Thérapie Cellulaire and Groupe Français d’étude de la Leu-
cémie Lymphoïd Chronique reported the results of their
randomized phase 3 trial for initial therapy [4]. The trial
enrolled 241 patients between 2001 and 2007. Patients
received initial therapy with mini-CHOP (CY, adriamycin,edgments on page 166.
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13.11.023vincristine, and prednisone) for 3 courses followed by 3
courses of ﬂudarabine. The overall response rate to induction
was 88.3% (complete remission [CR], 44.6%; partial remission
[PR], 43.7%). Patients in PR received further therapy with 1 or
2 cycles of DHAP (cisplatinum, cytarabine, and dexametha-
sone). Patients were then randomized to receive an unma-
nipulated autologous stem cell graft after CY and total body
irradiation (TBI) versus observation if in CR or versus ﬂu-
darabine and CY for 3 cycles if only in PR before treatment
with DHAP. Of patients randomized to autologous HCT, 27
(27.6%) did not receive assigned therapy (CR, 15 of 52; PR 12
of 46). Outcomes were affected by disease status after in-
duction. Patients in CR and assigned to autologous HCT had
79.8% (95% conﬁdence interval [CI], 69% to 92%) EFS at
3 years, compared with 35.4% (95% CI, 24% to 54%) in the
observation arm. Patients in PR had no improvement in EFS
after autologous HCT (HCT, 48.9% [95% CI, 35% to 68%]; ﬂu-
darabine and CY, 44.4% [95% CI, 32% to 62%]). Even though
HCT more than a doubled EFS for CR patients, OS was not
prolonged (HCT, 95.7% [95% CI, 90% to 100%]; observation,
97.8% [95% CI, 94% to 100%]), suggesting that salvage treat-
ment after relapse is effective.
The European Blood and Marrow Transplant Group
(EBMT) reported the results of their randomized trial
comparing autologous HCT (n¼ 112) to observation (n¼ 111)
after ﬁrst or second line therapy for patients with CLL [3]. In
this trial, induction therapy was not speciﬁed, but patients
were eligible for randomization only if they were in CR,
nodular PR, or very good PR. More than 80% of patients
enrolled after ﬁrst-line therapy (HCT, n ¼ 92; observation,
n ¼ 92) and 82 (73%) HCT patients and 83 (75%) observation
patients received at least 3 cycles of ﬂudarabine before
randomization. Notably, only 3 patients, all randomized to
observation, received FCR. All patients were mobilized with
either CY or Dexa-BEAM (carmustine, etoposide, cytarabine,
melphalan), and cells were cryopreserved for future use in
patients randomized to observation. Patients received con-
ditioning with either CY/TBI or BEAM. Similar to the results
of the Société Française de Greffe de Moelle et de Thérapie
Cellulaire/Groupe Français d’étude de la Leucémie Lymphoïd
Chronique trial, 5-year EFS was almost doubled after autol-
ogous HCT (HCT, 42%; observation, 24%; hazard ratio, .44Transplantation.
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(HCT, 85.5% [95% CI, 77% to 94%]; observation, 84.3% [95% CI,
75% to 93%]). The presence of 17p deletion or 11q deletion
was associated with 3.6-fold (95% CI, 2.05 to 6.31) greater
risk of death or progression.
More recently, the Groupe Ouest Est d’Etude des Leucé-
mies et autres Maladies du Sang reported the ﬁnal results of
the LLC 98 trial that enrolled patients (n ¼ 86) between 1999
and 2004 with a median follow-up of 77.1 months [5]. Pa-
tients randomized to chemotherapy received CHOP for 6
courses (n¼ 39) followed by either CHOP every 3 months for
6 additional cycles for patients with CR or PR or 3 to 6 cycles
of ﬂudarabine if less than a PR after CHOP. Those randomized
to autologous HCT (n ¼ 43) received 3 cycles of CHOP fol-
lowed by CY mobilization (for those patients in CR or very
good PR) or 1 to 3 cycles of ﬂudarabine (for those patients in
PR) and then CY mobilization.
Autologous HCT patients received CY/TBI conditioning
and a CD34-selected graft. This trial closed early due to
concerns regarding the lower efﬁcacy of chemotherapy with
CHOP as compared to ﬂudarabine. Additionally, only 29 pa-
tients (67.4%) received autologous HCT as assigned. Despite
these limitations, patients randomized to autologous HCT
had a median progression-free survival (PFS) of 53.1 months
(95% CI, 40.3 to 65.9) compared with only 22 months (95% CI,
12.6 to 31.3) for the maintenance arm. Once again, OS was
not affected with median survival after autologous HCT of
107.4 months (95% CI, 58.2 to 156.6) compared with
104.7 months (95% CI, 99.9 to 109.5) after maintenance
therapy.
As previously noted, nearly all patients in these trials
received what is now considered less than optimal front-line
induction therapy, and it is unclear whether the results of
these trials would differ if the current standard of FCR had
been used or whether HCT after induction with FCR could
improve OS. In an attempt to assess the impact of autologous
HCT compared with FCR alone, the German CLL group con-
ducted a retrospective cohort analysis comparing subsets of
patients treated on the CLL3 trial and the CLL8 trial [6,7].
Patients enrolled in the phase 2 CLL3 trial received induction
therapy with CHOP (n ¼ 93) or ﬂudarabine (n ¼ 14) or ﬂu-
darabine/CY (n¼ 54) for a median of 3 (range, 1 to 6) courses
followed by Dexa-BEAM for mobilization (n ¼ 156), and then
autologous HCT (n ¼ 131) with a B celledepleted graft after
CY/TBI conditioning. For this cohort comparison, patients
were included (CLL3, n ¼ 110; CLL8 [FCR], n ¼ 126) if they
were untreated, 60 years of age or younger, and had ﬂuo-
rescein in situ hybridization (FISH) and IGVH mutational
analyses completed. Once again, PFS was improved with
autologous HCT (median, 6.2 years) compared with chemo-
therapy alone (median, 4.3 years) but without improved OS
at 4 years (HCT, 86% [95% CI, 80% to 93%]; FCR, 90% [95% CI,
84% to 95%]).
In summary, autologous HCT in ﬁrst remission improves
DFS but does not yet improve OS. Consequently, autologous
HCT should not be considered outside of a clinical trial,
ideally investigating novel approaches to prevent relapse.
ALLOGENEIC HCT
Allogeneic HCT harnesses both the anticancer effects of
the conditioning regimen as well as the graft-versus-tumor
effects of the donor immune system. This potentially re-
sults in long-term DFS (ie, cure) for some patients with CLL
[8]. However, the toxicity and prolonged sequelae of alloge-
neic HCT and the generally older age of CLL patients haslimited this approach. The EBMT Consensus criteria recom-
mends allogeneic HCT for younger patients with nonre-
sponse or relapse less than 12 months from purine analogue
therapy; relapse at less than 24 months from purine
analogue combination therapy or autologous HCT; and in
patients with 17p abnormalities [9]. Several analyses
(Table 1) published recently highlight the improved out-
comes and applicability for this approach using reduced-
intensity conditioning (RIC) [10-15].
Sorror et al. reported outcomes for 82 patients with ﬂu-
darabine refractory CLL who received nonmyeloablative
conditioning with TBI 200 cGy  ﬂudarabine followed by
related (n ¼ 52) or unrelated (n ¼ 30) allogeneic HCT [12]. At
the time of HCT, 78 patients (95%) had measurable disease,
and the overall response rate was 70% (CR, 55%; PR, 15%). In
this series, the 5-year outcomes for OS, PFS, non-relapse
mortality (NRM), and relapse were 50%, 39%, 23%, and 38%
respectively. These outcomes are similar to those reported by
the MD Anderson Cancer Center group [13]. In this study, 86
patients with relapsed/refractory CLL received RIC condi-
tioning followed by either matched sibling (n ¼ 43) or un-
related (n ¼ 43) HCT. Nearly all patients (90.6%) received
conditioning with ﬂudarabine, CY, and high-dose rituximab
with tacrolimus and mini-methotrexate for graft-versus-
host disease (GVHD) prophylaxis. After HCT, 43 patients
had persistent or recurrent disease that was managed with
either rituximab, withdrawal of immune suppression, or
donor lymphocyte infusion. After these measures, 20 (47%)
patients had a CR, indicating a graft-versus-CLL effect.
Overall, 5-year PFS and OS were 36% (95% CI, 25% to 46%) and
51% (95% CI, 39% to 62%) respectively. More recently, Kharfan
et al. reported results of a novel reduced-toxicity condition-
ing regimen with pentostatin, i.v. busulfan, and rituximab
[16]. Nineteen (45%) of 42 patients had CLL;17 (89%) with
residual disease at time of HCT. After HCT, 10 (53%) of the CLL
patients had a CR, including 2 patients with stable or pro-
gressive disease at transplantation. An additional 5 (28%) of
the CLL patients obtained a PR compared with disease status
before HCT. At 2 years, the PFS and OS for the 19 CLL patients
were 55% (95% CI, 32% to 78%) and 66% (95% CI, 43% to 86%),
respectively. GVHD remains a barrier to successful allogeneic
HCT because of its contribution to NRM and its impact on
quality of life. In these studies, the risks of acute GVHD grade
II to IV ranged from a lowof 37% (95% CI, 27% to 47%) to a high
of 59% (95% CI, 43% to 75%) [12,13,16]. Chronic GVHD, cate-
gorized as extensive or moderate/severe, occurred in 49% to
58% of patients.
Various prognostic factors affect treatment responses in
patients with CLL. It appears, however, that allogeneic HCT
can overcome certain factors, including overexpression of
ZAP-70, 17p deletion, and in some cases, Richter’s trans-
formation [11,17,18]. For example, an analysis of 25 patients
with ZAP-70 overexpression and 13 patients without ZAP-70
overexpression at MD Anderson showed no statistically sig-
niﬁcant association with disease progression after HCT [17].
The EBMT analyzed 44 patients with 17p deletion who
received primarily (89%) RIC allogeneic HCT between 1995
and 2006 [11]. Overall survival at 3 years was 44% (95% CI,
28% to 60%) and PFS was 37% (95% CI, 22% to 52%), and no
relapses were observed beyond 4 years in this high-risk
group of patients. Assessments of both autologous and allo-
geneic HCT for patients with Richter’s transformation have
been recently reported as well [18]. For the 25 patients
receiving RIC allogeneic HCT, OS at 3 years was 36% (95% CI,
14% to 57%). Additional prognostic features that portend an
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sensitive disease, lymphadenopathy measuring less than
5 cm, and HLA-A1þ/A2-/B44- [12,13].
Allogeneic HCT clearly is an effective modality that can
result in long-term DFS for patients with high-risk features
and for those with relapsed or refractory disease. Limited
data suggest similar PFS, albeit a marginally inferior OS, for
patients receiving umbilical cord blood grafts comparedwith
patients receiving related donor mobilized blood cell grafts
[15]. The ultimate question remaining is the comparison of
allogeneic HCT versus ongoing chemo-immunotherapy.
Because this question is not likely to be assessed in a pro-
spective randomized or biologic assignment study, a Markov
decision analysis was used to suggest that the overall life
expectancy and quality-adjusted life expectancy were
improved by 10 months and 6 months, respectively, in favor
of RIC allogeneic HCT [19]. Consequently, it is reasonable to
consider RIC allogeneic HCT for most patients with high-risk
features or relapsed or refractory disease.
NOVEL CELLULAR THERAPIES
Recent publications demonstrate some efﬁcacy of novel
cellular approaches, including the use of chimeric antigen
receptoremodiﬁed T cells and autologous tumor vaccines
administered after RIC allogeneic HCT [20,21]. Proof of
principle for chimeric antigen receptoremodiﬁed T cells
speciﬁc for CD19, coupled with CD137 and CD3-zeta, was
reported for a patient with multiply relapsed CLL with 17p
deletion [20]. The patient received lympho-depleting
chemotherapy with pentostatin and CY followed by infu-
sion of 1.42  107 transduced cells over 3 infusions. The pa-
tient experienced tumor lysis syndrome, and at last report,
the disease remained in remission 10 months after the
infusion. A group from Dana Farber recently reported 2-year
outcomes for 22 patients enrolled in a phase I clinical trial of
a vaccine comprising 1  107 irradiated autologous tumor
cells mixed with 1 107 irradiated K562 bystander cells that
secrete granulocyte-macrophage colony stimulating factor
(GM-CSF) [21]. Patients received vaccination between day 30
and 45 after ﬂudarabine and busulfan RIC conditioning and
unmanipulatedmobilized blood cell grafts. Eighteen patients
received at least 1 vaccination. Clinical and biologic evidence
of immune responses were documented, and 2-year OS and
PFS were estimated at 88% (95% CI, 59% to 97%) and 82%
(95% CI, 54% to 94%), respectively. Both approaches appear
promising, and investigations are continuing.
CONCLUSIONS
Management of CLL continues to develop with new
agents and new cellular therapies. Furthermore, the hetero-
geneity of disease behavior and the myriad prognostic fac-
tors indicate a need for multiple therapeutic options. Based
on the current available data, autologous HCT should ideally
only be considered within a clinical trial with the option of
incorporating maintenance therapy or could be offered to
elderly ﬁt patients for whom an allogeneic HCT cannot be
considered. Based upon encouraging results after allogeneic
HCT with RIC, all patients younger than 65 years of age
should at least be referred to a transplantation center for
consideration and discussion of HCT.
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